Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Sangamo Therapeutics Inc (NASDAQ: SGMO) was $0.72 for the day, down -3.77% from the previous closing price of $0.75. In other words, the price has decreased by -$3.77 from its previous closing price. On the day, 3.48 million shares were traded. SGMO stock price reached its highest trading level at $0.7706 during the session, while it also had its lowest trading level at $0.7011.
Ratios:
Our analysis of SGMO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.03. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 1.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 150543776 and an Enterprise Value of 151854544. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.26 while its Price-to-Book (P/B) ratio in mrq is 6.35. Its current Enterprise Value per Revenue stands at 12.369 whereas that against EBITDA is -0.821.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $1.48, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 8.05%, while the 200-Day Moving Average is calculated to be 17.44%.
Shares Statistics:
SGMO traded an average of 14.42M shares per day over the past three months and 3778770 shares per day over the past ten days. A total of 208.22M shares are outstanding, with a floating share count of 198.81M. Insiders hold about 4.52% of the company’s shares, while institutions hold 41.86% stake in the company. Shares short for SGMO as of 1723680000 were 16093755 with a Short Ratio of 1.12, compared to 1721001600 on 12733283. Therefore, it implies a Short% of Shares Outstanding of 16093755 and a Short% of Float of 7.7700000000000005.
Earnings Estimates
The current rating of Sangamo Therapeutics Inc (SGMO) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.05, with high estimates of $0.16 and low estimates of -$0.14.
Analysts are recommending an EPS of between $0.02 and -$0.71 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.23, with 8.0 analysts recommending between $0.18 and -$0.59.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $146M, while the lowest revenue estimate was $1M, resulting in an average revenue estimate of $54.3M. In the same quarter a year ago, actual revenue was $176.23MBased on 8 analysts’ estimates, the company’s revenue will be $82.55M in the next fiscal year. The high estimate is $202M and the low estimate is $20M.
